Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Oligometastatic Gastrointestinal Cancer 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1BRAF V600E-mutated /MSS Metastatic Colorectal Cancer 1Advanced Tumors 1Advanced Solid Tumors 1Advanced Gastric Cancer 1Advanced Cervical Cancer 1

Interventions

Oxaliplatin 5S 1 (combination) 4Irinotecan 4pembrolizumab 3IFL protocol 3Fluorouracil 3Bevacizumab 3amminedichloro(2-methylpyridine)platinum(II) 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2MLN 8237 2Leucovorin 2Gemcitabine 2Folfox protocol 2Fecal Microbiota Transplantation 2Drug Therapy 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Capecitabine 2CGX1321 2ulixertinib 1tivozanib 1titanium silicide 1tislelizumab 1sodium thiosulfate 1sacituzumab govitecan 1remune 1plecanatide 1phosphatidyltransferase, Clostridium butyricum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Neoplasms × camrelizumab × Clear all
NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
99 enrolled
BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡